- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.25 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 3 | Investing.com | ||
| 17.12.25 | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | - | Investing.com Deutsch | ||
| 05.11.25 | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11.25 | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 190 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| 14.10.25 | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10.25 | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09.25 | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 376 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09.25 | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09.25 | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09.25 | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 7 | RTTNews | ||
| 26.08.25 | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 06.08.25 | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 06.08.25 | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08.25 | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.07.25 | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 3 | Investing.com | ||
| 08.07.25 | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 314 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 20.05.25 | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 171 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 280,83 | +1,85 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 77,92 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 20,140 | -2,09 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| BEAM THERAPEUTICS | 34,550 | +2,55 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| QIAGEN | 40,415 | 0,00 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,100 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,700 | -1,28 % | ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook | ||
| ALUMIS | 22,110 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,280 | +1,50 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 74,13 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,940 | -0,12 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,760 | -6,56 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| DYNE THERAPEUTICS | 17,040 | -2,41 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,75 | +2,90 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| NUVALENT | 101,17 | 0,00 % | FDA accepts Nuvalent's NDA for ROS1-positive NSCLC treatment |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 32,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.